These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 7503007)

  • 1. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
    Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
    Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone in congestive heart failure.
    Soberman JE; Weber KT
    Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
    Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients.
    MacFadyen RJ; Barr CS; Struthers AD
    Cardiovasc Res; 1997 Jul; 35(1):30-4. PubMed ID: 9302344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
    Zannad F
    Am J Cardiol; 1993 Jan; 71(3):34A-39A. PubMed ID: 8422003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
    Karram T; Abbasi A; Keidar S; Golomb E; Hochberg I; Winaver J; Hoffman A; Abassi Z
    Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1351-8. PubMed ID: 15894569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy.
    Pitt B
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):145-9. PubMed ID: 7786835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
    Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
    Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D
    Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
    van Vliet AA; Donker AJ; Nauta JJ; Verheugt FW
    Am J Cardiol; 1993 Jan; 71(3):21A-28A. PubMed ID: 8422000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
    Rousseau MF; Gurné O; Duprez D; Van Mieghem W; Robert A; Ahn S; Galanti L; Ketelslegers JM;
    J Am Coll Cardiol; 2002 Nov; 40(9):1596-601. PubMed ID: 12427411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
    Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.